1. Home
  2. TVRD vs ZVIA Comparison

TVRD vs ZVIA Comparison

Compare TVRD & ZVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • ZVIA
  • Stock Information
  • Founded
  • TVRD 2017
  • ZVIA 2007
  • Country
  • TVRD United States
  • ZVIA United States
  • Employees
  • TVRD N/A
  • ZVIA N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • ZVIA Beverages (Production/Distribution)
  • Sector
  • TVRD Health Care
  • ZVIA Consumer Staples
  • Exchange
  • TVRD Nasdaq
  • ZVIA Nasdaq
  • Market Cap
  • TVRD 246.5M
  • ZVIA 217.4M
  • IPO Year
  • TVRD N/A
  • ZVIA 2021
  • Fundamental
  • Price
  • TVRD $24.14
  • ZVIA $3.44
  • Analyst Decision
  • TVRD Strong Buy
  • ZVIA Buy
  • Analyst Count
  • TVRD 5
  • ZVIA 2
  • Target Price
  • TVRD $59.20
  • ZVIA $4.38
  • AVG Volume (30 Days)
  • TVRD 38.6K
  • ZVIA 702.9K
  • Earning Date
  • TVRD 08-21-2025
  • ZVIA 08-06-2025
  • Dividend Yield
  • TVRD N/A
  • ZVIA N/A
  • EPS Growth
  • TVRD N/A
  • ZVIA N/A
  • EPS
  • TVRD N/A
  • ZVIA N/A
  • Revenue
  • TVRD N/A
  • ZVIA $154,273,000.00
  • Revenue This Year
  • TVRD N/A
  • ZVIA $5.72
  • Revenue Next Year
  • TVRD N/A
  • ZVIA $6.83
  • P/E Ratio
  • TVRD N/A
  • ZVIA N/A
  • Revenue Growth
  • TVRD N/A
  • ZVIA N/A
  • 52 Week Low
  • TVRD $8.13
  • ZVIA $0.80
  • 52 Week High
  • TVRD $34.31
  • ZVIA $4.99
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • ZVIA 55.92
  • Support Level
  • TVRD N/A
  • ZVIA $3.20
  • Resistance Level
  • TVRD N/A
  • ZVIA $3.42
  • Average True Range (ATR)
  • TVRD 0.00
  • ZVIA 0.18
  • MACD
  • TVRD 0.00
  • ZVIA -0.00
  • Stochastic Oscillator
  • TVRD 0.00
  • ZVIA 66.07

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

Share on Social Networks: